DNMT1 and nasopharyngeal carcinoma: Decitabine, another DNMT inhibitor, is also undergoing clinical investigation in a phase I/II clinical trial (NCT03701451), where 30 NPC patients were received treatment with decitabine in combination with cisplatin-induced chemotherapy, followed by concurrent chemoradiotherapy.